Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1960 1
1966 1
1967 1
1968 1
1969 1
1971 3
1972 2
1973 4
1974 4
1975 1
1976 3
1977 2
1978 6
1979 5
1980 1
1981 1
1982 1
1984 1
1985 3
1986 2
1987 1
1988 2
1989 5
1990 2
1991 1
1992 3
1994 2
1995 2
1996 4
1997 5
1998 4
1999 6
2000 5
2001 4
2002 5
2003 12
2004 14
2005 13
2006 11
2007 11
2008 11
2009 7
2010 12
2011 14
2012 15
2013 16
2014 28
2015 34
2016 41
2017 42
2018 49
2019 57
2020 52
2021 59
2022 46
2023 55
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

652 results

Results by year

Filters applied: . Clear all
Page 1
Acidithiobacillia class members originating at sites within the Pacific Ring of Fire and other tectonically active locations and description of the novel genus 'Igneacidithiobacillus'.
Arisan D, Moya-Beltrán A, Rojas-Villalobos C, Issotta F, Castro M, Ulloa R, Chiacchiarini PA, Díez B, Martín AJM, Ñancucheo I, Giaveno A, Johnson DB, Quatrini R. Arisan D, et al. Among authors: johnson db. Front Microbiol. 2024 Apr 3;15:1360268. doi: 10.3389/fmicb.2024.1360268. eCollection 2024. Front Microbiol. 2024. PMID: 38633703 Free PMC article.
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Chen ST, et al. Among authors: johnson db. J Immunother Cancer. 2024 Apr 10;12(4):e007675. doi: 10.1136/jitc-2023-007675. J Immunother Cancer. 2024. PMID: 38599660 Free PMC article.
Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems.
Strayer N, Vessels T, Choi K, Zhang S, Li Y, Sharber B, Hsi RS, Bejan CA, Bick AG, Balko JM, Johnson DB, Wheless LE, Wells QS, Shah R, Philips EJ, Self WH, Pulley JM, Wilkins CH, Chen Q, Hartert T, Savona MR, Shyr Y, Roden DM, Smoller JW, Ruderfer DM, Xu Y. Strayer N, et al. Among authors: johnson db. medRxiv [Preprint]. 2024 Mar 30:2024.03.28.24305045. doi: 10.1101/2024.03.28.24305045. medRxiv. 2024. PMID: 38585743 Free PMC article. Preprint.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: johnson db. EClinicalMedicine. 2024 Mar 27;71:102564. doi: 10.1016/j.eclinm.2024.102564. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38572079 Free PMC article. No abstract available.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: johnson db. Nat Commun. 2024 Mar 26;15(1):2568. doi: 10.1038/s41467-023-44512-4. Nat Commun. 2024. PMID: 38531883 Free PMC article.
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Bai X, Lawless AR, Czapla JA, Gerstberger SC, Park BC, Jung S, Johnson R, Yamazaki N, Ogata D, Umeda Y, Li C, Guo J, Flaherty KT, Nakamura Y, Namikawa K, Long GV, Menzies AM, Johnson DB, Sullivan RJ, Boland GM, Si L. Bai X, et al. Among authors: johnson db. JAAD Int. 2024 Jan 19;15:105-114. doi: 10.1016/j.jdin.2023.11.014. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38500872 Free PMC article.
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: johnson db. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data.
Lippenszky L, Mittendorf KF, Kiss Z, LeNoue-Newton ML, Napan-Molina P, Rahman P, Ye C, Laczi B, Csernai E, Jain NM, Holt ME, Maxwell CN, Ball M, Ma Y, Mitchell MB, Johnson DB, Smith DS, Park BH, Micheel CM, Fabbri D, Wolber J, Osterman TJ. Lippenszky L, et al. Among authors: johnson db. JCO Clin Cancer Inform. 2024 Feb;8:e2300207. doi: 10.1200/CCI.23.00207. JCO Clin Cancer Inform. 2024. PMID: 38427922 Free PMC article.
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL, Taylor BC, Axelrod ML, Sun X, Guerin LN, Gonzalez-Ericsson PI, Wang Y, Sanchez V, Fahey CC, Sanders ME, Xu Y, Hodges E, Johnson DB, Balko JM. James JL, et al. Among authors: johnson db. J Immunother Cancer. 2023 Nov 20;11(11):e007736. doi: 10.1136/jitc-2023-007736. J Immunother Cancer. 2023. PMID: 38315170 Free PMC article.
652 results